Condition 1: Obese or overweight individuals with type 2 diabetes. Condition 2: Obese or overweight with type 2 diabetes. Type 2 diabetes mellitus Overweight and obesity
Conditions
Interventions
Intervention 1: First intervention group: Daily intake of 1.5 pieces of whole wheat lavash bread for 8 weeks (The composition of whole wheat lavash bread was determined by Bitaran Laboratory. The aver
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Overweight or obesity individuals aged 18 and above who either meet one of the diagnostic criteria for type 2 diabetes or have been diagnosed with diabetes and are taking medication to control their blood glucose
Exclusion criteria
Exclusion criteria: Insulin use Daily consumption of whole bread when examining people's dietary habits before the study began Pregnancy or breastfeeding Smoking or alcohol use Following special diets such as ketogenic, vegetarian, weight control diet, diabetic diet, etc. Chronic digestive disorders including chronic diarrhea, Crohn's and ulcerative colitis, and celiac disease Antibiotics taken within the past month Hospitalization within the past month Taking fiber supplements routinely or within the past month Individuals requiring a low-residue diet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fiber intake. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: 24-hour dietary recall (24hr).;Macronutrients intake. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: 24-hour dietary recall (24hr).;Micronutrients intake. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: 24-hour dietary recall (24hr).;Fasting blood sugar. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: Colorimetric method with Pars Azmoon kit and autoanalyzer.;2-hours postprandial glucose. Timepoint: At the beginning of the study and the end of the study (8 weeks after the intervention). Method of measurement: Colorimetric method with Pars Azmoon kit and autoanalyzer.;Hemoglobin A1C. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: Colorimetric method with Pars Azmoon kit and autoanalyzer.;Homeostasis model assessment-estimated insulin resistance (HOMA-IR) index. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: By calculating using the formula with using glucose and insulin.;Fasting insulin. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Body mass index. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: By calculating using the formula using height and weight.;Waist cir | — |
Secondary
| Measure | Time frame |
|---|---|
| High-sensitivity C-Reactive Protein. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Systolic blood pressure. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: Digital sphygmomanometer.;Diastolic blood pressure. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: Digital sphygmomanometer.;Triglyceride. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: Colorimetric method with Pars Azmoon kits and autoanalyzer.;HDL (high-density lipoprotein). Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: Colorimetric method with Pars Azmoon kits and autoanalyzer.;LDL (low-density lipoprotein). Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: Colorimetric method with Pars Azmoon kits and autoanalyzer.;Total cholesterol. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: Colorimetric method with Pars Azmoon kits and autoanalyzer.;Atherogenic index of plasma. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: By calculating with the formula using triglyceride and high-density Lipoprotein. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Mirshekaran
Shiraz University of Medical Sciences
Outcome results
None listed